A generic version of multiple sclerosis drug Copaxone was introduced in 2015, but it has done little to lower drug costs for MS patients, NPR reported. Yearly costs for MS drugs can run as high as $50 ...

(Reuters) - The U.S. Food and Drug Administration approved on Thursday the first generic version of Teva Pharmaceutical Industries Ltd's top-selling multiple sclerosis drug, Copaxone. The generic drug ...

ScinoPharm Taiwan (TWSE: 1789) today announced a landmark achievement in the global pharmaceutical landscape, securing U.

NEW YORK--(BUSINESS WIRE)--The overhanging risk of generic competition to Copaxone could prompt material top-line and profit losses at Teva Pharmaceutical Industries Ltd., according to Fitch Ratings.

TEL AVIV, July 14 (Reuters) - There will not be any generic version of Teva Pharmaceutical Industries' multiple sclerosis drug Copaxone before 2014, the company's president and chief executive said in ...

To say that Momenta Pharmaceuticals has been beaten down by Mr. Market in 2014 would be an understatement. The developmental-stage biotech has lost a lot of value since the beginning of the year ...

WASHINGTON — Teva Pharmaceutical on Wednesday was denied in its suit to block approval of Mylan's and Sandoz' generic Copaxone, a multiple sclerosis drug, 10 days before the patent on the medication ...

WASHINGTON (AP) — Supreme Court Chief Justice John Roberts on Friday declined to temporarily block a lower court ruling that opens the world’s best-selling multiple sclerosis drug to competition from ...

Shares of Teva Pharmaceutical Industries Ltd. climbed Monday in the first trading day after a federal court reaffirmed patents protecting the drugmaker's biggest brand-name product, the multiple ...

We are lowering our fair value estimate for Teva Pharmaceutical to $10 per share from $11, primarily as a result of our lower top-line forecast over the next two years. The company's first-quarter ...

NEW YORK (AP) -- Teva Pharmaceutical Industries said Monday the federal government is investigating its marketing of its multiple sclerosis drug Copaxone and Parkinson's disease treatment Azilect. The ...

Blue Cross and Blue Shield of Vermont and the Vermont Health Plan filed suit this week against Teva Pharmaceuticals, accusing the company of using some shady tactics to rake in money from its multiple ...